Shares of Enzymatica ENZY, +7.55% jumped 67% in Stockholm as the company said preliminary results show the ability of the mouth spray ColdZyme, in vitro, to deactivate SARS-CoV-2, the virus causing the COVID-19 pandemic. Stock on shelves in Sweden and other European Union countries was depleted by morning. Amazon, the world’s largest online retailer, is also backlogged with orders for ColdZyme.
A study demonstrated that ColdZyme deactivates SARS-CoV-2 coronavirus by 98.3%, the company said. That’s good enough for the public, who gobbled up the product on the market, and very good for Enymatica’s shareholders and investors. ColdZyme is the latest product to disappear from the market and pharmacy shelves as panicked shoppers around the world react to continuing COVID-19 outbreaks.
Claus Egstrand, Enzymatica’s chief operating officer spoke to the effectiveness of his company’s product. "Even if the current in vitro results cannot be directly translated into clinical efficacy, it is very interesting that ColdZyme is able to effectively deactivate SARS-CoV-2 in vitro since it constitutes a proof-of-principle that can be taken further into clinical studies. Thus, the results indicate that ColdZyme can offer a protective barrier against SARS-CoV-2."
As of press time, ColdZyme is “not currently available” and Amazon UK suppliers “don’t know when it will be available.”